A number of other research firms have also recently commented on GILD. Royal Bank Of Canada decreased their price objective on Gilead Sciences from $120.00 to $105.00 and set an outperform rating on the stock in a report on Tuesday, July 26th. Needham & Company LLC lowered Gilead Sciences from a buy rating to a hold rating and boosted their target price for the company from $84.60 to $88.55 in a research report on Tuesday, July 26th. Jefferies Group reissued a hold rating and issued a $93.00 target price (down previously from $97.00) on shares of Gilead Sciences in a research report on Tuesday, July 26th. Piper Jaffray Cos. cut their target price on Gilead Sciences from $114.00 to $108.00 and set an overweight rating on the stock in a research report on Tuesday, July 26th. Finally, Robert W. Baird reissued an outperform rating and issued a $122.00 target price (down previously from $135.00) on shares of Gilead Sciences in a research report on Tuesday, July 26th. Nine research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $105.26.
Gilead Sciences (NASDAQ:GILD) opened at 80.62 on Thursday. The company has a 50-day moving average price of $79.46 and a 200 day moving average price of $85.79. The company has a market cap of $106.39 billion, a PE ratio of 7.08 and a beta of 1.06. Gilead Sciences has a 52 week low of $76.67 and a 52 week high of $111.11.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. During the same period in the prior year, the firm posted $3.15 earnings per share. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. On average, equities research analysts forecast that Gilead Sciences will post $11.76 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.33%. Gilead Sciences’s dividend payout ratio (DPR) is 16.56%.
In other news, Chairman John C. Martin sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $84.73, for a total transaction of $8,473,000.00. Following the completion of the transaction, the chairman now directly owns 4,119,727 shares of the company’s stock, valued at approximately $349,064,468.71. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO John F. Milligan sold 112,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the transaction, the chief executive officer now directly owns 1,170,963 shares of the company’s stock, valued at $98,747,309.79. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Evercore Wealth Management LLC boosted its position in shares of Gilead Sciences by 1.0% in the second quarter. Evercore Wealth Management LLC now owns 457,553 shares of the biopharmaceutical company’s stock worth $38,169,000 after buying an additional 4,467 shares during the period. Carnick & Kubik Group LLC acquired a new position in shares of Gilead Sciences during the second quarter worth $1,060,000. Kentucky Retirement Systems Insurance Trust Fund acquired a new position in shares of Gilead Sciences during the second quarter worth $4,486,000. Kentucky Retirement Systems acquired a new position in shares of Gilead Sciences during the second quarter worth $9,448,000. Finally, KAMES CAPITAL plc boosted its position in shares of Gilead Sciences by 2.9% in the second quarter. KAMES CAPITAL plc now owns 335,796 shares of the biopharmaceutical company’s stock worth $28,005,000 after buying an additional 9,407 shares during the period. 77.94% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.